In This Section

Home / Blurb / Discussion List

FDA Approves Pembrolizumab for Melanoma

Feb 19, 2019, 11:07 AM
On February 15, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co.) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Read the FDA press release here.

Posted 2/19/2019

Leave a comment